Beyond these documented effects, high-dose crizotinib therapy has been shown to trigger immunogenic cell death (ICD) in cancer cells lacking the intended ALK/ROS1 mutations, suggesting potential off-target effects beyond the drug’s primary mechanism [90,91]. The gene discussed is ALK; the disease is cancer.